An initial phase I clinical trial demonstrated clinical activity of taselisib in patients with advanced solid tumors, particularly in breast cancers with PIK3CA genetic alterations, with an overall response of 36% compared to no response in patients with wild-type PIK3CA [89]. This evidence concerns the gene PIK3CA and breast cancer.